For example, GWAS in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) identified IL23R, IL12B, and IL17A as associated loci, facilitating the development of ustekinumab, an IL12/23 inhibitor used in PsA, and secukinumab, an IL17A inhibitor used in both AS and PsA (41, 42). This evidence concerns the gene IL17A and ankylosing spondylitis.